Peanut Protein and Increased Tolerated Peanut Protein Dose

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Of the doses administered at home during the first year of OIT, 1.4% resulted in adverse events and 79% were mild
from: High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small
adverse eventsReported1.4% of doses resulted in adverse events
Of the doses administered at home during the first year of OIT, 1.4% resulted in adverse events and 79% were mild
from: High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small
epinephrine administrationReportedthree doses of epinephrine were given at home to two individuals
three doses of epinephrine were given at home to two individuals
from: High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small

1 of 1 paper

High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial.